Discover 161 paid clinical trials in Honolulu, Hawaii. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 161
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
for
Medulloblastoma
Location: Honolulu HI, Stanford CA, Oakland CA, Sacramento CA,
Sponsor: Giselle Sholler
Sex: All
Age: 0 - 21
Code: NCT04696029
Phase2, Recruiting
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
for
Hematopoietic and Lymphoid Cell Neoplasm,
Location: Honolulu HI, San Francisco CA, Oakland CA,
Sponsor: Children's Oncology Group
Sex: All
Age: 2 - 18
Code: NCT05711667
Phase3, Recruiting
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
for
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer,
Location: Honolulu HI, Milwaukee WI, Atlanta GA, Lebanon NH
Sponsor: OncoTherapy Science, Inc.
Sex: All
Age: 18+
Code: NCT02926690
Phase1, Recruiting
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
for
Atypical Teratoid/Rhabdoid Tumor,
Location: Honolulu HI, Dallas TX, Kansas City KS, Little Rock AR,
Sponsor: Milton S. Hershey Medical Center
Sex: All
Age: 0 - 26
Code: NCT06465199
Phase1, Phase2, Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Location: Honolulu HI, San Francisco CA, Palo Alto CA, Oakland CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 30
Code: NCT04546399
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
for
Malignant Glioma
Location: Honolulu HI, San Francisco CA, Palo Alto CA, Oakland CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 21
Code: NCT05099003
Phase1, Phase2, Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
for
B Acute Lymphoblastic Leukemia
Location: Honolulu HI, San Francisco CA, Palo Alto CA, Oakland CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 1 - 46
Code: NCT06124157
Phase2, Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
for
Recurrent Langerhans Cell Histiocytosis,
Location: Honolulu HI, San Francisco CA, Palo Alto CA, Oakland CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 22
Code: NCT05828069
Phase2, Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
for
Hematologic Malignancies, Inherited Disorders of Metabolism,
Location: Honolulu HI, San Francisco CA, Stanford CA,
Sponsor: Center for International Blood and Marrow Transplant Research
Sex: All
Age: 0+
Code: NCT01351545
Recruiting
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Location: Honolulu HI, San Francisco CA, Palo Alto CA, Oakland CA,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT04322318
Phase2, Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
for
Childhood Medulloblastoma
Location: Honolulu HI, San Francisco CA, Oakland CA,
Sponsor: Children's Oncology Group
Sex: All
Age: 4 - 21
Code: NCT05382338
Phase3, Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study